Iranian Journal of Pathology

Differential IDH1 Immunohistochemical Expression Across the Pathologically Stratified Spectrum of Intraepithelial and Invasive Laryngeal Squamous Cell Lesions

Articles in Press

Document Type : Original Research

Authors

Nora Tawhid Abdelfattah El-Zohery 1
Sara Mohamad Abou-Fandoud 1
Asmaa Mohamed Saad Zaghloul Attaalla 2
Abeer Mohammed Amal Mohammed 1

1 Department of Anatomic Pathology, Faculty of Medicine, Kasr Alainy Hospital, Cairo University, Cairo, Egypt

2 Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Kasr Alainy Hospital, Cairo University, Cairo, Egypt

10.30699/ijp.2025.2067116.3495
Abstract
Background & Objective: Laryngeal carcinoma is a common head and neck cancer with high morbidity and mortality. This study evaluates IDH1 immunohistochemical expression in pre-invasive and invasive laryngeal squamous cell lesions, its correlation with clinicopathological features, and its prognostic and therapeutic potential.
Methods: A retrospective analysis of 65 laryngeal squamous cell lesion cases was conducted using IDH1 immunohistochemistry.
Results: IDH1 expression significantly correlated with invasion status (intensity and H-score; p = 0.026, 0.025) and histopathological progression and grade (p = 0.033, 0.036). Two-year DFS and OS were 81.5% and 69%, respectively, with no significant association between survival outcomes and IDH1 H-score (p = 0.851, 0.225).
Conclusion: According to our findings, increased IDH1 expression may be associated with features of aggressive tumor behavior and could hold clinical significance in laryngeal squamous cell lesions, potentially serving as a future therapeutic target.

Keywords

Laryngeal neoplasms
Squamous cell carcinoma of head and neck
Isocitrate dehydrogenase 1
Immunohistochemistry
Precancerous conditions

Subjects

1.      Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today [Internet]. Lyon (FR): International Agency for Research on Cancer; 2022 [cited 2025 May 13]. Available from: https://gco.iarc.fr/today.
2.      Igissin N, Zatonskikh V, Telmanova Z, Tulebaev R, Moore M. Laryngeal cancer: epidemiology, etiology, and prevention: a narrative review. Iran J Public Health. 2023;52(11):2248-59.  [DOI:10.18502/ijph.v52i11.14025] [PMID] [PMCID]
3.      Santos A, Santos IC, Dos Reis PF, Rodrigues VD, Peres WAF. Impact of nutritional status on survival in head and neck cancer patients after total laryngectomy. Nutr Cancer. 2021;74(5):1252-60.    [DOI:10.1080/01635581.2021.1952446] [PMID]
4.      Zhang SY, Lu ZM, Luo XN, Chen LS, Ge PJ, Song XH, et al. Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment. PLoS One. 2013;8(4):e60157. [PMID] [PMCID]      [DOI:10.1371/journal.pone.0060157]
5.      Kim DH, Kim SW, Han JS, Kim GJ, Basurrah MA, Hwang SH. The prognostic utilities of various risk factors for laryngeal squamous cell carcinoma: a systematic review and meta-analysis. Medicina (Kaunas). 2023;59(3):497.   [DOI:10.3390/medicina59030497] [PMID] [PMCID]
6.      Zhao Y, Qin J, Qiu Z, Guo J, Chang W. Prognostic role of neutrophil-to-lymphocyte ratio to laryngeal squamous cell carcinoma: a meta-analysis. Braz J Otorhinolaryngol. 2020;88(5):717-24.      [DOI:10.1016/j.bjorl.2020.09.015] [PMID] [PMCID]
7.      Carbonneau M, Gagne LM, Lalonde ME, Germain MA, Motorina A, Guiot MC, et al. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat Commun. 2016;7(1):12700.        [DOI:10.1038/ncomms12700] [PMID] [PMCID]
8.      Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18(10):645-61. [DOI:10.1038/s41571-021-00521-0] [PMID]
9.      Varachev V, Shekhtman A, Guskov D, Rogozhin D, Zasedatelev A, Nasedkina T. Diagnostics of IDH1/2 mutations in intracranial chondroid tumors: comparison of molecular genetic methods and immunohistochemistry. Diagnostics (Basel). 2024;14(2):200. [DOI:10.3390/diagnostics14020200] [PMID] [PMCID]
10.    Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30. [DOI:10.1016/j.ccr.2010.12.014] [PMID] [PMCID]
11.    Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-7. [DOI:10.1158/1078-0432.CCR-09-0715] [PMID]
12.    Priambada D, Arifin MT, Saputro A, Muzakka A, Karlowee V, Sadhana U, et al. Immunohistochemical expression of IDH1, ATRX, Ki67, GFAP, and prognosis in Indonesian glioma patients. Int J Gen Med. 2023;16(1):393-403.             [DOI:10.2147/IJGM.S397550] [PMID] [PMCID]
13.    Shayanfar N, Zare-Mirzaie A, Mohammadpour M, Jafari E, Mehrtash A, Emtiazi N, et al. Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2023;149(8):4253-67. [DOI:10.1007/s00432-022-04336-z] [PMID] [PMCID]
14.    Al-Amodi HSAB, Nabih ES, Kamel HFM, El Sayed MA, Dwedar IAM. Wild-type isocitrate dehydrogenase 1 over-expression is related to cancer stem cells survival in lung adenocarcinoma. Cancer Invest. 2018;36(3):185-9.    [DOI:10.1080/07357907.2018.1445262] [PMID]
15.    Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, et al. The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 2010;29(1):43. [DOI:10.1186/1756-9966-29-43] [PMID] [PMCID]
16.    Yang H, Xie S, Liang B, Tang Q, Liu H, Wang D, et al. Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-fluorouracil. J Cancer. 2021;12(16):4862-72. [DOI:10.7150/jca.58846] [PMID] [PMCID]
17.    Xu C, Ooi WF, Qamra A, Tan J, Chua BYJ, Ho SWT, et al. HNF4α pathway mapping identifies wild-type as a targetable metabolic node in gastric cancer. Gut. 2020;69(2):231-42. [DOI:10.1136/gutjnl-2018-318025] [PMID]
18.    Huang J, Tseng LH, Parini V, Lokhandwala PM, Pallavajjala A, Rodriguez E, et al. IDH1 and IDH2 mutations in colorectal cancers. Am J Clin Pathol. 2021;156(5):777-86. [DOI:10.1093/ajcp/aqab023] [PMID]
19.    Li J, Huang J, Huang F, Jin Q, Zhu H, Wang X, et al. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer. Oncotarget. 2016;7(45):73638-50. [DOI:10.18632/oncotarget.12039] [PMID] [PMCID]
20.    Shayanfar N, Zare-Mirzaie A, Mohammadpour M, Jafari E, Mehrtash A, Emtiazi N, et al. Determination of isocitrate dehydrogenase (IDH1) mutation in laryngeal squamous cell carcinoma specimens. Research Square [Preprint]. 2022 [cited 2025 May 13]. Available from: https://doi.org/10.21203/rs.3.rs-1629748/v1 [DOI:10.21203/rs.3.rs-1629748/v1.]
21.    WHO Classification of Tumours Editorial Board. Head and neck tumours. 5th ed. Geneva: World Health Organization; 2024. (WHO classification of tumours; vol 9).
22.    Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 8th ed. Chichester (UK): Wiley-Blackwell; 2017. [DOI:10.1002/9780471420194.tnmc26.pub3]
23.    Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. [DOI:10.3322/caac.21708] [PMID]
24.    Wang L, Peng J, Wen B, Zhai Z, Yuan S, Zhang Y, et al. Contrast-enhanced computed tomography-based machine learning radiomics predicts IDH1 expression and clinical prognosis in head and neck squamous cell carcinoma. Acad Radiol. 2025;32(2):976-87. [DOI:10.1016/j.acra.2024.08.038] [PMID]
25.    Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, et al. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild-type intrahepatic cholangiocarcinoma. Sci Rep. 2022;12(1):18775. [DOI:10.1038/s41598-022-22543-z] [PMID] [PMCID]
26.    Cho U, Yang SH, Yoo C. Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience. J Int Med Res. 2021;49(6):03000605211019258. [DOI:10.1177/03000605211019258] [PMID] [PMCID]
27.    Tlemsani C, Heske CM, Elloumi F, Pongor L, Khandagale P, Varma S, et al. Sarcoma_CellminerCDB: a tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines. iScience. 2024;27(6):109918.  [DOI:10.1016/j.isci.2024.109781] [PMID] [PMCID]
28.    Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-6. [DOI:10.1212/WNL.0b013e3181f96282] [PMID]
29.    Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH. IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep. 2012;28(5):1639-46. [DOI:10.3892/or.2012.1994] [PMID]
30.    Husain A, Mishra S, Siddiqui MH, Husain N. Detection of IDH1 mutation in cfDNA and tissue of adult diffuse glioma with allele-specific qPCR. Asian Pac J Cancer Prev. 2023;24(3):961-7.        [DOI:10.31557/APJCP.2023.24.3.961] [PMID] [PMCID]
Iranian Journal of Pathology

Articles in Press, Accepted Manuscript
Available Online from 20 February 2026

  • Receive Date 27 July 2025
  • Revise Date 31 October 2025
  • Accept Date 23 December 2025

Home

Guide for Authors

Submit Manuscript

Contact Us